Clinical Trials · NCT00577824
Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 181
- Start date
- Jan 2008
- Locations
- 12 sites, Japan
- Primary endpoint
- Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24